NCT07021092 PERSON-CENTERED APPROACHES TO VIREMIA: CONNECTION, RAPPORT, AND ENGAGEMENT STUDY
| NCT ID | NCT07021092 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre for Infectious Disease Research in Zambia |
| Condition | HIV Viremia |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2027-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,000 participants in total. It began in 2025-04-01 with a primary completion date of 2027-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to increase the reach of the person-centred interpersonal practices by developing and accessing a tailored, scalable, and sustainable approach that meets the distinctive needs of populations identified as most disproportionately affected by viremia in Zambia. The study population include pregnant and breastfeeding women, children, adolescents and adult that are more than thirty -30 days late for their next hospital appointments.The study will be implemented over a period of 36 months in 24 facilities in Lusaka and Central province, Zambia.
Eligibility Criteria
Inclusion Criteria: 1. Patients that are lost to follow up (\[LTFU\] from HIV care i.e. confirmed \>30 days late for a scheduled appointment) at the time of sampling. (i.e. not people who were previously LTFU but then returned and have a documented VL.) 2. Individuals returning to care after being out of care and not taking ART with no VL measure (i.e., unmeasured viremia) 3. Patients that are 6 months late for a scheduled Viral Load (VL) according to Ministry of Health guidelines at the time of sampling (regardless of care status) 4. Patients that have a last documented VL that is elevated, \> 1000 copies/ml at time of sampling in current clinic population (CCP) (regardless of care status) 5. Participant that are willing to provide written informed consent in English, or any of the local languages that include Nyanja or Bemba. Exclusion Criteria: 1. Patients that are unable to provide consent or unwilling to participate in the study 2. Participant who is NOT living with HIV/AIDS; 3. Participant is too sick i.e., failing to talk, general discomfort and emergency cases);
Contact & Investigator
Dr Aaloke Mody
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT07021092 clinical trial?
This trial is open to participants of all sexes, studying HIV Viremia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07021092 currently recruiting?
Yes, NCT07021092 is actively recruiting participants. Contact the research team at Kombatende.Sikombe@cidrz.org for enrollment information.
Where is the NCT07021092 trial being conducted?
This trial is being conducted at Lusaka, Zambia, Lusaka, Zambia.
Who is sponsoring the NCT07021092 clinical trial?
NCT07021092 is sponsored by Centre for Infectious Disease Research in Zambia. The principal investigator is Dr Aaloke Mody at Washington University School of Medicine. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.